Semaglutide
FDA-approved GLP-1 receptor agonist with the largest clinical evidence base for weight and glycemic outcomes.
31 residues· First described 2012
GLP-1 analog with Aib substitution at position 2 + C18 fatty diacid acylation at Lys26 for albumin binding
Overview
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist originally developed by Novo Nordisk and approved under the brand names Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management). It was the first GLP-1 with clinical trial data showing sustained double-digit percentage body weight reduction, and remains the most clinically studied compound in the class, with the STEP trials showing ~15% average weight loss at 68 weeks at the maintenance dose.
Beyond weight and glycemic effects, semaglutide has shown cardiovascular risk reduction in the SELECT trial, with favorable movement in biomarkers like ApoB, triglycerides, HbA1c, and hs-CRP. These secondary effects are often what matters most for long-term health, and they're the reason serious users track a full metabolic panel rather than just the scale.
The titration schedule is critical - most GLP-1 side effects (nausea, GI intolerance) are concentration- and rate-of-change-dependent. Users who titrate slower than the box recommends almost uniformly report a better experience than those who follow the label exactly. Logging dose, injection date, and side effects alongside biomarkers gives a clear picture of personal response.
Mechanism of Action
Semaglutide mimics endogenous GLP-1, a gut-derived incretin hormone. It acts on pancreatic beta cells (glucose-dependent insulin secretion), alpha cells (glucagon suppression), the hypothalamus (appetite reduction), and the GI tract (delayed gastric emptying). The result is reduced appetite, improved glycemic control, and - over months - sustained weight reduction primarily from fat mass. Cardiovascular benefits appear to be mediated through improved metabolic parameters and direct anti-inflammatory effects on vascular tissue.
Community Usage Patterns
Standard titration per label: 0.25 mg weekly × 4 weeks, 0.5 mg × 4, 1.0 mg × 4, 1.7 mg × 4, then 2.4 mg maintenance. Many users extend each step to 6–8 weeks to minimize GI side effects. Compounded versions from 503A pharmacies are common and typically reconstituted in 2–3 mL of bacteriostatic water. Key tracking: weight weekly, HbA1c and fasting glucose at baseline + 3 months + 6 months, ApoB quarterly.
Education only - not medical advice. Any protocol change should involve your licensed provider.
Biomarkers to Track
When running Semaglutide, these are the biomarkers most commonly tracked to assess response and safety:
Reconstitution Calculator
Free calculator for Semaglutide reconstitution math - vial size, BAC water volume, and exact syringe units.
Open Semaglutide calculator →Related Reading
Related Peptides
Semaglutide Head-to-Head Comparisons
Conditions Semaglutide is Commonly Researched For
Log doses, upload your lab PDFs, and let StackAI read your panel in context of what you're actually running. Free to start.
Start tracking →This page is informational and does not constitute medical advice. MyProtocolStack is a tracking and education platform. Work with a licensed provider before starting, changing, or stopping any protocol.